Literature DB >> 6375067

Natural history and staging of prostate cancer.

W F Whitmore.   

Abstract

The natural history and staging of prostatic cancer, directly or indirectly, involve natural expectancy of the host, malignant potential of the tumor, extent of the tumor, and response of the tumor to treatment. Discussion of these topics is followed by a description of the systems of clinical staging of the disease.

Entities:  

Mesh：

Year:  1984        PMID： 6375067

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  20 in total

Review 1.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

2.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Authors:  Jehonathan H Pinthus; Tova Waks; Victoria Malina; Keren Kaufman-Francis; Alon Harmelin; Itzhak Aizenberg; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.

Authors:  D Mannini; P Maver; E Aiello; G Corrado; F Vecchi; B Bellanova; M Marengo
Journal:  Urol Res       Date:  1988

Review 4.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.

Authors:  Vaios Hatzoglou; Gita V Patel; Michael J Morris; Kristen Curtis; Zhigang Zhang; Weiji Shi; Jason Huse; Marc Rosenblum; Andrei I Holodny; Robert J Young
Journal:  J Neuroimaging       Date:  2012-12-28       Impact factor: 2.486

6.  Clinical characteristics and prognostic factors of prostate cancer with liver metastases.

Authors:  HaiTao Wang; BaoGuo Li; PengYu Zhang; YanHong Yao; JiWu Chang
Journal:  Tumour Biol       Date:  2014-01

7.  AgNOR quantity in needle biopsy specimens of prostatic adenocarcinomas: correlation with proliferation state, Gleason score, clinical stage, and DNA content.

Authors:  D Trerè; A Zilbering; D Dittus; P Kim; P C Ginsberg; I Daskal
Journal:  Clin Mol Pathol       Date:  1996-08

8.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

Review 9.  Background to and management of treatment-related bone loss in prostate cancer.

Authors:  Alfredo Berruti; Marcello Tucci; Carlo Terrone; Gabriella Gorzegno; Roberto M Scarpa; Alberto Angeli; Luigi Dogliotti
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer.

Authors:  J L Ware
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.